Asset Details
Do you wish to reserve the book?
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
Do you wish to request the book?
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
2019
Overview
Oral use of the selective FLT3 kinase inhibitor gilteritinib in patients who had relapsed or refractory acute myeloid leukemia with
FLT3
mutations led to a median overall survival of 9.3 months (vs. 5.6 months with standard chemotherapy) and complete remission with full or partial hematologic recovery in 34.0% of patients (vs. 15.3%).
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Aniline Compounds - adverse effects
/ Aniline Compounds - therapeutic use
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - therapeutic use
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Death
/ Female
/ fms-Like Tyrosine Kinase 3 - genetics
/ Humans
/ Leukemia, Myeloid, Acute - drug therapy
/ Leukemia, Myeloid, Acute - genetics
/ Leukemia, Myeloid, Acute - mortality
/ Male
/ Mutation
/ Survival
